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Summary and Key Points 
1. Over eighty different compounds have been approved to treat 
cancer. Their mechanisms of action, effectiveness against specific 
cancers, and potential toxicity vary greatly. 
2. Cytotoxic chemotherapy agents kill by damaging essential cellular 
components. It is useful to consider these compounds by their 
mechanism of action: 
a. Alkylators damage DNA by adding a carbon adduct 
covalently to specific bases. 
b. Platinum analogues, like alkylators, covalently add platinum 
to DNA. 
c. Topoisomerase inhibitors damage DNA by interfering with 
the action of an enzyme needed for unwinding DNA for 
replication and transcription. 
d. Microtubule inhibitors disrupt mitosis by damaging the 
structure needed for the physical separation of 
chromosomes into daughter cells. 
e. Antimetabolites interfere with DNA synthesis by depleting 
pools of nucleotides. 
3. “Targeted Therapies” refer to agents that interact with a specific 
cell target to kill or inhibit cell growth. 
a. Hormonal agents interfere with hormones that stimulate 
cancer growth. 
b. Kinase inhibitors interfere with specific growth factor 
receptors or intracellular messengers that have a tyrosine 
kinase function. 
c. Antibodies bind specifically to protein targets on the surface 
of cancer cells. 
4. Immune therapy of cancer has only recently become a widely 
applied modality of care. 
a. Checkpoint inhibitors disrupt regulatory components of the 
immune response to permit immune-mediated destruction of 
tumors. 
b. Cytokines such as interferon and interleukin-2 are now rarely 
used to treat cancer. 
c. Despite much hope, no vaccine has ever effectively treated 
cancer. 
Introduction 
What we now call cancer, the uncontrolled and ultimately lethal over-
growth of tumor cells, has been recognized for many centuries. However, 
the systematic development of drugs to kill cancer cells dates back only 
70 years when biologic warfare studies demonstrated the ability of 
mustard compounds to destroy lymphocytes and bone marrow cells, and 
ultimately, lymphoma cells. The first class of anti-tumor drugs is now 
known as the alkylating agents. Over the following 50 years, many other 
classes of drugs came into clinical use, collectively known as cytotoxic 
drugs, directly damaging DNA, interfering with the synthesis and 
replication of DNA, and impairing function of the mitotic spindle. 
During the late 1990’s, the quest for new cancer cell toxins gave way to 
the development of “targeted” agents, mainly in the form of monoclonal 
anti-bodies and small molecule kinase inhibitors that interfere with 
receptor function and signaling cascades. The hope is that biologic 
processes unique to cancer cells can be drug targets and that normal 
cells can be spared “off target” effects, thus avoiding many of the 
toxicities associated with chemotherapy. 
This chapter will describe, in terms of mechanism of action, the most 
important classes of cytotoxic and targeted therapies as well as their 
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most characteristic side effects and clinical uses. Table 1, summarizing 
the classes of drugs and representative members of those classes, is 
included at the end of the chapter. Rather than an encyclopedia, this will 
be a schematic diagram or roadmap to more detailed knowledge that you 
will acquire during your clinical training and subsequent experience. The 
modern pharmacology texts such as Katzung1, Golan2, and others will 
build on this framework. 
The Cytotoxics 
Alkylating agents were the first modern anti-cancer drugs. The nitrogen 
mustards, initially used to kill soldiers during the trench warfare of World 
War I, were later shown to be particularly destructive to lymphocytes and 
to bone marrow cells. Early clinical trials demonstrated their ability to 
shrink lymphoma tumor masses. The unifying mechanism of action is 
transformation of a pro-drug to an active compound from which an alkyl 
group is detached, which binds covalently to nucleophilic groups such as 
N1 and N3 adenine, resulting in interstrand cross-linking of the DNA 
double helix. This results in base pair mismatches, base excisions and 
DNA strand breakage, which then trigger the process of “programmed” 
cell death, known as apoptosis. 
The prototype alkylating agent is cyclophosphamide, activated in the liver 
via P 450 enzymes. The drug is most often used to treat breast cancer 
and the non-Hodgkin lymphomas. Side effects include suppression of the 
red and white blood cells and platelets (myelosuppression), nausea and 
vomiting, hair loss, ovarian/testicular failure and late occurrence of 
leukemia. 
Similar in mechanism of action to the classic alkylators are the platinum 
drugs, which covalently bind platinum to bases in the same DNA strand 
instead of across strands, like classic alkylators. The result of intrastrand 
covalent cross-linking is the same-direct DNA damage that triggers 
apoptosis. 
Three different platinum drugs- Cisplatin, Carboplatin, and Oxaliplatin are 
clinically important and share the same mechanism of action. Each 
platinum compound has distinctive clinical uses and toxicity profiles: 
• They all depend on renal excretion and have the potential to 
damage the kidney, though cisplatin has the greatest potential 
for nephrotoxicity. 
• They have a broad spectrum of anti-tumor activity and are 
among our most useful cytotoxic drugs. 
• They produce bone marrow suppression to varying degrees. 
Cisplatin and Oxaliplatin cause peripheral sensory neuropathy. 
The third class of cytotoxics to be discussed, the antimetabolites, was 
historically the next class developed after the alkylators, beginning with 
the work of Dr Sydney Farber in Boston in the late 1940’s. The generic 
definition of an antimetabolite is a compound that mimics the structure of 
purines and pyrimidines- the building blocks of DNA/RNA - and/or 
inhibits the enzymes that synthesize these building blocks and 
incorporate them into DNA/RNA. 
The earliest example of an antimetabolite, methotrexate, inhibits the 
enzyme, dihydrofolate reductase (DHFR), critical for methyl group 
transfers in purine synthesis. It is important to note that the antibiotic 
trimethoprim (frequently combined with a sulfa antibiotic in clinical use) 
inhibits bacterial DNA DHFR by the same mechanism. 
The most commonly used antimetabolites today are fluorouracil and its 
oral prodrug capecitabine. Both of these drugs impact DNA synthesis by 
inhibiting the enzyme thymidylate synthase, essential in pyrimidine 
synthesis/incorporation into DNA. 
Fluorouracil and capecitabine are most important in the treatment of 
gastrointestinal cancers, particularly colon cancer. Capecitabine is also 
used in the treatment of breast cancer. Diarrhea, mouth sores and bone 
marrow suppression are their most important side effects. 
We have so far discussed drugs which directly damage DNA-the 
alkylators and platinums, which interfere with purines and pyrimidine 
synthesis and incorporation into DNA/RNA –the antimetabolites. We 
move now to an important class of drugs which interfere with function of 
the enzyme family called topoisomerases. These enzymes break, uncoil 
and religate DNA strands during the complex process of replicating the 
double helix. Without topoisomerase’s function, DNA replication cannot 
occur. 
The most important group of topoisomerase inhibitors is the 
anthracyclines, which inhibit topoisomerase II, resulting in DNA strand 
breaks, thereby triggering apoptosis. In addition, these drugs generate 
free radicals which may be particularly important in causing damage to 
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heart muscle. This menacing toxicity limits the amount of anthracycline 
that can be given. Cumulative doses above a well-defined threshold 
produce a rapidly escalating probability of heart failure, which 
pathologically is due to myocardial necrosis. 
Doxorubicin (almost always called by its original proprietary name 
Adriamycin) is the prototype anthracycline. It has potent anti tumor 
activity against multiple tumor types, including breast cancer, 
lymphomas, acute leukemia and soft tissue sarcomas. In addition to 
heart damage, doxorubicin and related drugs cause severe hair loss, 
bone marrow suppression, tissue necrosis when extravasated during IV 
administration, and vomiting-especially when combined with other drugs 
e.g. cyclophosphamide. 
The inhibitors of topoisonmerase I also interfere with the critical 
processes of breakage, uncoiling and relegation of DNA strands during 
replication. The prototype drug irinotecan is important in the treatment of 
gastrointestinal cancers. Its main toxicities are hair loss, bone marrow 
suppression and diarrhea. It does not cause cardiac toxicity. 
The final classes of cytotoxic drugs we will consider damage the mitotic 
spindle, which guides duplicated chromosomes to daughter cells. The 
mitotic spindle is built of assemblies of microtubules, which act as 
“tracks” for the chromosomes. They are in a constant state of assembly 
and disassembly. 
Well in advance of detailed knowledge of microtubule biology, the vinca 
alkaloids, derived from the periwinkle plant, were developed over forty 
years ago. They bind to ᵝ-tubulin, one of the proteins making up 
microtubules, and prevent tubulin / microtubule polymer assembly. 
The prototype vinca alkaloid, vincristine, is now used almost exclusively 
in the treatment of lymphoma. The most important vinca in current 
oncological practice is vinorelbine, which is particularly useful in treating 
breast cancer and lung cancer. Like the platinum compounds, the vinca 
alkaloids have different side effect profiles. The parent compound, 
vincristine, is not myelosuppressive but causes substantial neurotoxicity. 
Vinorelbine causes much less neurotoxicity, and bone marrow 
suppression limits its dosing. The vinca alkaloids cause little hair loss 
and little nausea/vomiting. 
The second group of “spindle poisons” is also plant derived, from the 
yew tree, and are the taxanes. Two important drugs, paclitaxel and 
docetaxel, prevent disassembly of the microtubules, i.e. they 
“hyperstabilize” and in so doing disrupt the function of microtubules. Both 
of these drugs are useful in a broad range of tumor types, including 
breast cancer, lung cancer, head and neck cancer and ovarian cancer. 
Like the vinca alkaloids they produce peripheral neuropathy. They also 
cause hair loss and myelosuppression. Because of their formulation, 
which has to include a detergent to get them into aqueous solution, they 
frequently cause allergic reactions. 
Targeted Therapies 
Targeted therapy implies drug treatment directed at a particular tumor 
cell biologic characteristic such as expression of the estrogen receptor or 
over-expression of the HER2 gene. In the first example, many breast 
cancers will shrink when estrogen, the ligand of the receptor, is withheld. 
In the second example, binding of the HER2 receptor with a monoclonal 
antibody, or inhibition of the tyrosine kinase activity of the receptor 
(which triggers a signaling pathway), will cause shrinkage of most HER2 
breast cancers. 
An early approach to “targeted” therapy occurred in 1896, when an 
English surgeon, Beatson, carried out oophorectomy in an attempt to 
treat advanced breast cancer. His understanding of sex steroid 
physiology was embryonic, but the concept of removing a female 
reproductive organ to treat a cancer occurring almost exclusively in 
women was the beginning of what we call hormonal or endocrine 
therapy. Armed with the knowledge that estrogen stimulates proliferation 
of breast cancer cells that express the estrogen receptor and that 
testosterone, in similar fashion, stimulates proliferation of prostate cancer 
cells, most of which express the androgen receptor, multiple strategies to 
deprive these tumors of their growth factors have been devised. 
In 1941, Huggins and his colleagues demonstrated that castration of 
rodents with prostate cancer resulted in regression of prostate cancer. 
Androgen deprivation remains the cornerstone of treating metastatic 
prostate cancer today, and is now accomplished pharmacologically 
instead of by surgical castration. 
The pituitary gland, which secretes Follicle Stimulating Hormone (FSH) 
and Luteinizing Hormone (LH) does so in response to pulsatile signaling 
from the hypothalamus with luteinizing hormone releasing hormone 
(LHRH). When the signal becomes monophasic, for example after a 
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large parenteral dose of an LHRH analog such as goserelin or leuprolide, 
the pituitary cannot respond and gonadotropin signaling stops with the 
consequence that testosterone production in the testicles ceases. In like 
fashion, LHRH analogs suppress of ovarian estrogen production. 
Seventy per cent of men with prostate cancer experience tumor 
regression with testosterone deprivation, and 50-60% of women with 
estrogen receptor positive (ER+) breast cancer experience tumor 
regression with estrogen deprivation. 
Ovarian suppression in breast cancer is most effective in pre 
menopausal women, whose ovaries are producing large quantities of 
estrogen. Another strategy for estrogen deprivation is to block the 
estrogen receptor with tamoxifen, a drug developed in Worcester during 
the late 1960’s.3 Tamoxifen is a competitive inhibitor of estrogen binding 
to the estrogen receptor. It has both estrogen agonist and antagonist 
properties and is frequently referred to as a selective estrogen receptor 
modulator (SERM). Hence, it typically acts as an estrogen antagonist in 
breast tissue, making it useful in treating advanced breast cancer, in 
reducing recurrence late in early stage breast cancer and in preventing 
breast cancer in many women at high risk. Tamoxifen’s estrogen 
antagonist property is also responsible for the most common side effect 
of the drug, hot flashes. The estrogen agonist function of tamoxifen 
produces the beneficial result of reducing the risk of osteoporosis and 
fracture. However, estrogen activity of tamoxifen is the cause of 
increased risks of uterine cancer and deep vein thrombosis associated 
with the drug. 
An alternative strategy of estrogen deprivation, effective only in 
postmenopausal women with ER+ disease, is to inhibit or inactivate the 
enzyme aromatase, which catalyzes the transformation of steroid 
precursors into estrogens. The so called aromatase inhibitors, with 
anastrozole the prototype compound, have essentially the same 
therapeutic indications as tamoxifen-with the main difference being that 
anastrozole and its cousins letrozole and exemestrane work only in post 
menopausal women. Side effect profiles are also different. Because they 
produce near total elimination of circulating estrogens, the aromatase 
inhibitors accelerate bone loss and can cause joint discomfort. However, 
they do not increase the risks of uterine cancer or thrombosis. 
A final agent causing estrogen deprivation to treat breast cancer is the 
drug fulvestrant, given as a monthly intra muscular injection. This drug 
accelerates degradation of the estrogen receptor and down regulates its 
production. Since it has no agonist activity it has been called a pure anti-
estrogen. Currently it is used only to treat advanced disease. Its major 
toxicity is menopausal symptoms. 
The study of breast cancer biology has yielded other important targets 
for drug treatment, particularly the HER2 (also called erb2 or neu) cell 
surface receptor and its intracellular kinase which activates signaling 
cascades concerned with proliferation and cell maintenance. A 
monoclonal antibody binding to the extracellular domain of HER2, 
Trastuzumab (commonly known as Herceptin) has revolutionized the 
treatment of HER2 over-expressing breast cancers of every stage. In 
addition, the small molecule, lapatinib, which blocks phosphorylation of 
the intracellular tyrosine kinase activity of HER2, has also come into 
clinical use in breast cancer. 
The model for monoclonal antibody directed against a surface receptor 
target is also clinically exploited in the treatment of non Hodgkin 
lymphoproliferative disorders with the anti-CD20 antibody, rituximab, and 
the treatment of colorectal cancer with the EGFR monoclonal antibody 
cetuximab. 
In general, because monoclonal antibodies have high specificity for their 
binding sites, these drugs produce mild toxicities related mainly to 
infusion reactions (they are all given IV). However trastuzumab can 
cause (usually mild) cardiac toxicity, rituximab can cause leucopenia and 
immunosuppression and cetuximab can cause rash and diarrhea. 
Monoclonal antibodies used in cancer treatment are “humanized” and 
typically have very long half-lives. This permits them to be given 
relatively infrequently (weekly to every other month) and yet still maintain 
circulating blood levels of the drugs throughout treatment. 
In this century kinase inhibitors have become a common class of 
“targeted” oral anti-cancer drugs. Preventing phosphorylation by 
intracellular kinases which drive proliferation has been exploited most 
elegantly and effectively with the development of imatinib, the small 
molecule tyrosine kinase inhibitor which emerged as a “miracle drug” in 
the treatment of chronic myelocytic leukemia. Imatinib and its 
descendants interrupt the constitutive activation of the bcr-abl protein in 
CML, shutting down the hyper proliferation of myeloid cells and 
delaying/preventing the previously inevitable progression to a fatal acute 
leukemia-like blast crisis. Interruption of the bcr-abl activity results in 
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suppression of the malignant CML clone(s) as evidenced by 
normalization of cytogenetics and in many patients, suppression of the 
bcr-abl protein product. 
In keeping with the hopes for targeted therapy, imatinib toxicity is 
minimal and only rarely necessitates stopping treatment. However, 
imatinib also demonstrates that so-called “targeted” kinase inhibitors can 
have multiple targets. The stem cell factor receptor and platelet derived 
growth factor receptor are both inhibited be imatinib. While inhibition of 
these other targets has been exploited by using imatinib to treat other 
malignancies (gastrointestinal stromal tumor and hypereosinophilia 
syndrome), additional targets may also mediate some of the side effects 
of the drug. Subsequent kinase inhibitors have often had even more side 
effects than imatinib, generally because many of them can interfere with 
multiple kinases. 
At this point there are over twenty kinase inhibitors available to treat 
various cancers. All are oral drugs. Like imatinib, some are only used if a 
cancer expresses a particular target inhibited by the drug. For example, 
erlotinib inhibits the tyrosine kinase activity of the epidermal growth factor 
receptor (EGFR) and is used to treat lung cancers that harbor activating 
mutations in EGFR. However, many kinase inhibitors are used to treat an 
array of cancers regardless of the presence of a specific mutation. 
Examples are sunitinib, useful in renal cell cancer and sorafenib, one of 
the first drugs to be effective to any degree in treating primary liver 
cancer. These compounds are really “multi-targeted” kinases and 
interfere with a number of intracellular proteins. They tend to cause many 
more side effects than seen with more specific kinase inhibitors, like 
imatinib. 
 
Some targeted therapies have been designed based on the concept of 
anti-angiogenesis, or blocking tumor blood vessel formation. The 
concept, originally articulated and demonstrated in the laboratory by the 
late Judah Folkman at Children’s Hospital Boston, proposes that tumor 
growth can be halted by preventing the development of the new blood 
vessels needed to nourish/oxygenate tumor masses. The drugs which 
have anti-angiogenic activity are drawn from several classes. The 
monoclonal antibody, bevacizumab, binds to the vascular endothelial 
growth factor receptor called, VEGF. The tyrosine kinase inhibitors 
sunitinib and sorafenib, discussed above, inhibit intra-cellular signaling 
pathways that drive angiogenesis. The immunomodulatory agents, 
thalidomide and lenalidomide, inhibit new blood vessel formation by 
uncertain mechanism. Much remains to be learned regarding the precise 
mechanisms by which these varied agents inhibit tumor blood vessel 
development. 
Immune Therapy 
Using the immune system to treat cancer has been a goal of medicine 
for at least the last century. There have been many attempts to develop 
vaccines, cytokines, and antibodies to treat cancer immunologically. 
Despite much hope and promise, no cancer vaccine has been effective. 
Cytokines such as interferon and interleukin-2 do have activity against 
some cancers and are approved by the FDA, but their activity is limited 
and they have significant toxicity. Only in the last few years has there 
been a real breakthrough in immune therapy of cancer. 
The human body clearly can generate an immune response to cancers. 
A biopsy of a cancer will frequently show a large number of tumor-
infiltrating lymphocytes (TIL) within the tumor. Some studies have 
correlated the presence of TIL with better outcomes in some cancers 
(melanoma, breast). However, despite the presence of an immune 
response, most cancers evade immune surveillance. One mechanism by 
which this is accomplished is using checkpoints on regulatory T cells to 
shut down the immune response. In the last few years a number of 
antibodies have been developed that inhibit these checkpoints. 
Ipilumumab binds CTLA-4, and pembrolizumab and nivolumab bind to 
PD-1. All of these drugs are antibodies and their respective targets are 
protein receptors on regulatory T cells that are used to down-regulate the 
immune response. Antibody binding to these receptors inhibits their 
function and prevents shut down of the immune response. Ipilumumab is 
approved for treatment of melanoma and pembrolizumab and nivolumab 
are approved for treatment of melanoma, non-small cell lung cancer, and 
renal cell cancer. These drugs can cause prolonged remissions of 
cancer. The major side effects of the drugs are, not surprisingly, auto-
immune toxicities. Autoimmune colitis, pneumonitis, and 
endocrinopathies have been the most commonly observed side effects. 
Toxicity seems to be greater with ipilumumab than the other antibodies, 
possibly because CTLA-4 is expressed earlier in regulatory T cell 
development than PD-1, and so inhibition of CTLA-4 may result in 
broader immune regulatory suppression. Additional checkpoint inhibitors 
are in development, and it is likely that additional cancers will be treated 
with these drugs in the future. 
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Conclusion 
Space and the immense volume of information demanding your attention 
have precluded a comprehensive review of all the important drugs and a 
more detailed description of mechanisms of action, clinical uses and 
toxicities. As noted in the introduction, this diagram or roadmap, will 
serve as a skeleton which will be “fleshed out” as your clinical training 
and experience unfold. 
The biology of cancer is complex and dynamic with tumor biology 
evolving during the course of an individual patient’s illness and 
treatment. Biology of cancer cells and normal cells overlaps extensively, 
what we describe as clinical cancer represents the behavior of multiple 
clones or families of tumor cells which are heterogeneous because of an 
increased DNA mutation rate, resulting in a daunting challenge for anti 
cancer drug treatment. 
Table 1. Classes of Drugs Reviewed in this Chapter 
1. Cytotoxic Agents 
a. Alkylators 
Nitrogen Mustard, Cyclophosphamide 
b. Platinum Compounds 
Cisplatin, Carboplatin, Oxaliplatin 
c. Antimetabolites 
Methotrexate, Fluorouracil, Capecitabine 
d. Topoisomerase Inhibitors 
Doxorubicin, Irinotecan 
e. Microtubule Binding Agents 
Vincristine, Vinorelbine, Paclitaxel, Docetaxel 
2. Targeted Therapies 
a. Hormonal Therapies 
Leuprolide, Goserelin, Tamoxifen, Anastrozole, Letrozole, 
Exemestane, Fulvestrant 
b. Antibodies 
Trastuzumab, Rituximab, Bevacizumab, Cetuximab 
c. Tyrosine Kinase Inhibitors 
Imatinib, Sunitinib, Sorafenib, Erlotinib, Lapatinib 
d. Immune Modulators 
Thalidomide, Lenalidomide 
3. Immune Therapy 
a. Checkpoint Inhibitors 
Ipilumumab, Pembrolizumab, Nivolumab 
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Thought Questions 
1. Anti-cancer drugs are frequently used in combinations. The goal of 
combination chemotherapy is to increase tumor cell kill without 
causing unacceptable toxicity. What drugs might be difficult to 
combine together? For example, what might be the consequence of 
concurrent treatment with doxorubicin and trastuzumab? What 





























2. One uncommon but very serious late side effect of alkylating agents 
and topoisomerase inhibitors is the development of myelodysplasia 
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3. The monoclonal antibodies cetuximab and panitumomab both target 
the extracellular domain of EGFR and are effective in the treatment 
of colon cancer. However, colon cancers that have mutations in 
KRAS are completely resistant to treatment with these antibodies. 
What could be the mechanism of resistance of cells with KRAS 





























4. A very common mechanism of resistance to many chemotherapy 
drugs is the expression of a cell surface protein on cancer cells 
called mdr (for multi-drug resistance; it has also been called P170). 
Mdr is an ATP-dependent “pump” that transports molecules out of 
the cell. Planar, lipophilic molecules tend to be good substrates for 
mdr. Interestingly, many chemotherapy drugs derived from natural 
sources are transported out of cancer cells by mdr. Which 
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Glossary 
Mechanism of action- How a drug interacts with a target 
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